普萘洛尔联合腹水引流治疗肝硬化顽固性腹水临床观察  

Clinical observation of propranolol combined with ascites drainage for the treatment of refractory ascites in cirrhosis

作　　者：程瑾[1] 叶泉忠[1] 翁慧斌[1] 胡建华[1] 

机构地区：[1]浙江中医药大学附属医院衢州市人民医院消化内科,浙江省衢州324000

出　　处：《中国基层医药》2014年第3期344-346,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 观察普萘洛尔联合腹腔穿刺腹水引流治疗各种原因肝硬化顽固性腹水的疗效.方法 回顾性分析76例肝硬化顽固性腹水患者的临床资料,其中45例予普萘洛尔联合腹水引流治疗（观察组）,31例患者予常规治疗（对照组）,比较两组治疗的有效率.结果 观察组腹水明显减少及消失29例,有效率64.4%（29/45）;对照组腹水明显减少及消失8例,有效率25.8%（8/45）;两组差异有统计学意义（χ^2=10.97,P〈0.01）.结论 普萘洛尔联合腹腔穿刺腹水引流是治疗肝硬化顽固性腹水行之有效的方法.Objective To observe the efficacy of propranolol combined with intraperitoneal ascites drainage for the treatment of intractable ascites in cirrhosis induced by various causes. Methods The clinical data of 76 cir- rhosis patients with intractable ascites were retrospectively analyzed. 45 cases were treated by propranolol and ascites drainage （ observation group）, and 31 patients were treated with conventional therapy （ control group）. The treatment efficacy of the two groups was compared. Results In the observation group,ascites of 29 patients decreased and disappeared, the effective rate was 64.4% （29/45）. In the control group, ascites of 8 cases decreased and disappeared, the effective rate was 25.8% （ 8/45 ）, there was significant difference between the two groups （ X^2 = 10.97, P 〈 0, 01 ）. Conclusion Propranolol combined with aseites drainage is an effective way to treat refractory ascites in cirrhosis.

关 键 词：肝硬化 腹水 普萘洛尔 引流术 腹水液 

分 类 号：R575.2[医药卫生—消化系统]